Rare Disease Biotechs Add Jobs as Approvals Advance
BioSpace highlights four rare-disease-focused biotechs that are recruiting. Scholar Rock, one of them, recently won FDA approval for Isembyld to treat spinal muscular atrophy in patients aged 2 and older already receiving SMN2-targeted therapy. The company is also testing apitegromab in a Phase 2 trial for FSHD and lists 30 job openings.
Scholar Rock, founded 2012 in Cambridge, has 30 openings. Its platform targets protein growth factors before activation. Isembyld, formerly apitegromab-mtsn, won FDA clearance for SMA patients aged 2+ already on SMN2-targeted therapy. Apitegromab also has fast track and orphan designations for FSHD; Phase 2 FORGE dosing is underway.
Insmed, founded 1988 in Bridgewater, New Jersey, lists over 100 roles. It spans respiratory, immunology/inflammation, and neuro/rare disease. Approved Arikayce treats NTM lung disease. Gene therapies INS1201 for DMD and INS1202 for ALS are in Phase 1. An AI deimmunization platform is being explored for redosable gene therapies.
The hiring push may expand capacity to develop and deliver rare-disease therapies, potentially benefiting patients with SMA, FSHD, DMD, ALS, and NTM lung disease, along with their caregivers. New roles could strengthen clinical trials, manufacturing, and regulatory work, though whether these treatments reach more people may depend on pricing, insurance coverage, and health-system readiness. For biopharma workers, the openings could offer specialized careers in small patient populations with high unmet need.